Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer

Nature

Volumn 542, Issue 7642, 2017, Pages 484-488

  Zhao, Di ^a   Lu, Xin ^a   Wang, Guocan ^a   Lan, Zhengdao ^a   Liao, Wenting ^a   Li, Jun ^a   Liang, Xin ^a   Chen, Jasper Robin ^a   Shah, Sagar ^a   Shang, Xiaoying ^a   Tang, Ming ^a   Deng, Pingna ^a   Dey, Prasenjit ^a   Chakravarti, Deepavali ^a   Chen, Peiwen ^a   Spring, Denise J ^a   Navone, Nora M ^a   Troncoso, Patricia ^a   Zhang, Jianhua ^a   Wang, Y Alan ^a   DePinho, Ronald A ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CHD1 PROTEIN; DNA BINDING PROTEIN; DNA HELICASE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BTRC PROTEIN, HUMAN; CHD1 PROTEIN, HUMAN; HISTONE; PTEN PROTEIN, HUMAN;

CANCER; CHROMOSOME; DEGRADATION; DNA; GENE EXPRESSION; GENOME; MUTATION; PROTEIN; TUMOR;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; ESSENTIAL GENE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TUMOR SUPPRESSOR GENE; UBIQUITINATION; BREAST TUMOR; CHEMISTRY; DEFICIENCY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHYLATION; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; PROTEIN STABILITY; TUMOR CELL LINE;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA HELICASES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ESSENTIAL; GLYCOGEN SYNTHASE KINASE 3 BETA; HISTONES; HUMANS; LYSINE; MALE; METHYLATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; NF-KAPPA B; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; PTEN PHOSPHOHYDROLASE; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 85016157905     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21357     Document Type: Article

References (30)

1. Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068 (1997).
2. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
3. Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337-342 (2012).
4. Cairns, P. et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997-5000 (1997).
5. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003).
6. Fece de la Cruz, F., Gapp, B. V. & Nijman, S. M. Synthetic lethal vulnerabilities of cancer. Annu. Rev. Pharmacol. Toxicol. 55, 513-531 (2015).
7. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
8. Nijhawan, D. et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150, 842-854 (2012).
9. Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
10. Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22, 398-406 (2012).
11. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
12. Dillon, L. M. & Miller, T. W. Therapeutic targeting of cancers with loss of PTEN function. Curr. Drug Targets 15, 65-79 (2014).
13. Mason, J. M. et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell 26, 163-176 (2014).
14. Huang, S. et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31, 4164-4170 (2012).
15. Burkhardt, L. et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 73, 2795-2805 (2013).
16. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015).
17. Rodrigues, L. U. et al. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 75, 1021-1034 (2015).
18. Hart, M. et al. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr. Biol. 9, 207-210 (1999).
19. Zhao, B., Li, L., Tumaneng, K., Wang, C. Y. & Guan, K. L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(β-TRCP). Genes Dev. 24, 72-85 (2010).
20. Strack, P. et al. SCF(β-TRCP) and phosphorylation dependent ubiquitination of IκBa catalyzed by Ubc3 and Ubc4. Oncogene 19, 3529-3536 (2000).
21. Fuchs, S. Y., Spiegelman, V. S. & Kumar, K. G. The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23, 2028-2036 (2004).
22. Flanagan, J. F. et al. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 438, 1181-1185 (2005).
23. Gaspar-Maia, A. et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460, 863-868 (2009).
24. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-κ B as the matchmaker. Nat. Immunol. 12, 715-723 (2011).
25. Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D. & Fidler, I. J. Blockade of NF-κ B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20, 4188-4197 (2001).
26. Jin, R. et al. Inhibition of NF-κ B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene 34, 3700-3710 (2015).
27. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
28. Wan, X. et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 6, 252ra122 (2014).
29. Garber, M. et al. A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol. Cell 47, 810-822 (2012).
30. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417-425 (2015).